drugset
drugset / Trial / NCT04492618

Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica

NCT04492618 ↗

Phase 2 Completed 12 enrolled Aaron R. Mangold
NaSingle-groupOpen-labelTreatment

Summary

This research study is evaluating the safety and efficacy of a topical drug treatment "Ruxolitinib" in treating Necrobiosis Lipoidica (NL).

Timeline

Start
2020-09-29
Primary completion
2022-03-16
Completion
2022-03-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule 1.5 % Topical

Indications

necrobiosis lipoidica